NIPH Clinical Trials Search

UMIN ID: UMIN000001519

Registered date:01/12/2008

Treatment protocol for adult acute lymphocytic leukemia -ALL/ MRD2008-

Basic Information

Recruitment status Complete: follow-up continuing
Health condition(s) or Problem(s) studiedadult acute lymphocytic leukemia
Date of first enrollment2008/12/01
Target sample size20
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)In adult BCR/ABL negative ALL, the indication of allogeneic HSCT will be determined by the MRD status. High-risk patients will proceed to allogeneic HSCT. Low-risk patients will proceed to maintenance treatment which is less toxic than HSCT. In adult BCR/ABL positive ALL, patients will receive induction therapy combined with imatinib. Every patient will proceed to allogeneic HSCT whenever possible.


Primary Outcome3 years disease-free survival
Secondary Outcome5 years disease free survival, CR rate, treatment-related toxicities

Key inclusion & exclusion criteria

Age minimum16years-old
Age maximum65years-old
GenderMale and Female
Include criteria
Exclude criteria1. B-ALL(L3) of the blast cell cell surface immune globulin positive 2. A case having double cancers 3. A case with an infectious disease having difficulty with control 4. A case with a severe mental disorder 5. The pregnancy or breast-feeding woman 6. the case that the medical attendant judged to be inappropriate

Related Information


public contact
Name Toshihiro Miyamoto
Address 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan Japan
Telephone 092-642-5230
Affiliation Kyushu University Hospital Hematology/Oncology
scientific contact
Name Koji Nagafuji
Address 67 Asahi-machi, Kurume 830-0011, Japan Japan
Telephone 0942-31-7852
Affiliation Kurume University School of Medicine Hematology/Oncology